Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $7.8 million.

  • C4 Therapeutics' Cash from Financing Activities fell 2601.37% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year decrease of 9238.16%. This contributed to the annual value of $45.3 million for FY2024, which is 33.63% down from last year.
  • Per C4 Therapeutics' latest filing, its Cash from Financing Activities stood at $7.8 million for Q3 2025, which was down 2601.37% from -$46000.0 recorded in Q1 2025.
  • In the past 5 years, C4 Therapeutics' Cash from Financing Activities registered a high of $170.5 million during Q2 2021, and its lowest value of -$10.8 million during Q3 2023.
  • Its 5-year average for Cash from Financing Activities is $15.1 million, with a median of $310000.0 in 2022.
  • Within the past 5 years, the most significant YoY rise in C4 Therapeutics' Cash from Financing Activities was 12260638.3% (2023), while the steepest drop was 307867.04% (2023).
  • C4 Therapeutics' Cash from Financing Activities (Quarter) stood at $466000.0 in 2021, then plummeted by 89.91% to $47000.0 in 2022, then soared by 122606.38% to $57.7 million in 2023, then plummeted by 99.81% to $112000.0 in 2024, then surged by 6840.18% to $7.8 million in 2025.
  • Its Cash from Financing Activities was $7.8 million in Q3 2025, compared to -$46000.0 in Q1 2025 and $112000.0 in Q4 2024.